Crossmark

Low-dose CT screening — determining the right interval

Crossref DOI link: https://doi.org/10.1038/nrclinonc.2016.106

Published Online: 2016-07-12

Published Print: 2016-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yankelevitz, David

Henschke, Claudia
License Information

Text and Data Mining valid from 2016-07-12
More Information

Article History

First Online: 12 July 2016

Competing interests

: D.Y. is a named inventor on a number of patents and patent applications relating to the evaluation of diseases of the chest, including measurement of nodules. Some of these, which are owned by Cornell Research Foundation (CRF) are non-exclusively licensed to General Electric. As an inventor on these patents, D.Y. is entitled to a share of any compensation that CRF might receive from the commercialization of these patents. D.Y. is also an equity owner in Accumetra, a privately held technology company committed to improving the science and practice of image-based decision making. C.H. is a named inventor on a number of patents and patent applications relating to the evaluation of pulmonary nodules on CT scans of the chest, which are owned by CRF, but does not accept any financial benefit from these patents, including royalties and any other proceeds related to the patents or patent applications owned by CRF, since 2009.